PT - JOURNAL ARTICLE AU - Jun Miyata AU - Toby Winton-Brown AU - Thomas Sedlak AU - Toshihiko Aso AU - Nicola Cascella AU - Jennifer Coughlin AU - Nicolas A. Crossley AU - Emrah Duezel AU - Takahiro Ezaki AU - Masaki Fukunaga AU - Carolyn Howell AU - Masanori Isobe AU - Kouhei Kamiya AU - Kiyoto Kasai AU - Takanori Kochiyama AU - Shinsuke Koike AU - Akira Kunimatsu AU - Naoki Masuda AU - Susumu Mori AU - Yasuo Mori AU - Toshiya Murai AU - Kiyotaka Nemoto AU - Frederick Nucifora AU - Kazutaka Ohi AU - Naohiro Okada AU - Yuki Sakai AU - Nobukatsu Sawamoto AU - Tsutomu Takahashi AU - Shinichi Urayama AU - Yoshiyuki Watanabe AU - Crystal C. Watkins AU - Hidenaga Yamamori AU - Yuka Yasuda AU - Ryota Hashimoto AU - Hidehiko Takahashi AU - Akira Sawa AU - Philip McGuire TI - Trait, staging, and state markers of psychosis based on functional alteration of salience-related networks in the high-risk, first episode, and chronic stages AID - 10.1101/2021.10.02.21264326 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.02.21264326 4099 - http://medrxiv.org/content/early/2021/10/04/2021.10.02.21264326.short 4100 - http://medrxiv.org/content/early/2021/10/04/2021.10.02.21264326.full AB - Objective Salience is a critical mechanism for survival in animals, the alteration of which is postulated to play key role in psychosis, including the hippocampus-midbrain-striatal and anterior cingulate cortex (ACC)-insular (salience network: SN) systems. However, how these two systems contribute to the psychosis traits, staging, and state is unknown.Methods Eight scanners at seven sites recruited 29 ultra-high-risk (UHR) individuals and 25 matched healthy controls (HC), 81 first-episode psychosis (FEP) patients and 109 HC, and 99 chronic psychosis (ChrP) patients and 145 HC. Resting-state functional MRI data which were intensively denoised and site effect-removed revealed the two systems as comprising five networks: the medial temporal lobe network (MTLN), midbrain-thalamic and striatal parts of the basal ganglia network (BGN-MbThal and BGN-Str), and ACC and insular parts of the SN (SN-ACC and SN-Ins). Group difference and correlation with positive symptom of network measures were performed in each psychosis stage.Results Connectivity within the BGN-MbThal was reduced in FEP compared to HC (p<0.05, family-wise-error [FWE] corrected). Connectivity within the SN-ACC was reduced in UHR (p<0.05, FWE) and in FEP and ChrP at liberal thresholds, with effect size of UHR>FEP>ChrP. FEP showed increased brain-state instability among the five networks, and positive correlation between positive symptom and connectivity within and between the MTLN. The correlation was stronger in unmedicated than medicated, and in affective than non-affective psychosis patients (all p<0.05, FWE).Conclusions Two salience-related systems were associated with psychosis traits, staging, and state. Refining these findings will lead to the development of clinically usable biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by JSPS/MEXT KAKENHI grants 26461767 (JM), 17H04248 (JM), 18H05130 (JM), 20H05064 (JM), 19H03583 (HT), 23120009 (HT), 16H06572 (HT), 20K21567 (HT), 15H04893 (TM), 16H06397 (TM), JP16H06280 (KK), JP18K07550 (TT), and JP21K12153 (KN); JST ImPACT grant 15808865 (TM) and Moonshot R&D grant JPMJMS2021 (SK and KK); grants from the Japan Foundation for Aging and Health (HT); AMED Strategic Research Program for Brain Sciences grants 17dm0107044h0005 (HT) and 20dm0107088h0005 (TM), Brain/MINDS & beyond studies 21dm0307008h0004 (JM, HT), 20dm0307102h0002 (TM), JP21dm0307001 (KK), JP21dm020769 (KK), JP21dm0307004 (SK and KK), and JP21dm0307002 (RH), Brain Mapping by Integrated Neurotechnologies for Disease Studies JP20dm0207069 (SK and KK), and grants JP21dk0307103 (RH) and JP21uk1024002 (RH); Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders of NCNP (RH); Novartis Pharma Research Grant (JM); a grant from SENSHIN Medical Research Foundation (JM, HT); a grant from SUZUKEN Memorial Foundation (JM); Tanabe-Mitsubishi Pharma Research Grant (JM); a grant from Uehara memorial foundation; Kyoto University Global Frontier Project for Young Professionals (JM); Takeda Science Foundation (JM and HT); Kobayashi Magobei Memorial Foundation (HT); Smoking Research Foundation (HT); the Kato Memorial Trust for Nambyo Research (TM); the National Institute of Mental Health (NIMH) grant numbers MH-094268 (AS), MH-092443 (AS), MH-105660 (AS), and the Silvio O. Conte Center funded by NIMH (AS); the National Institute of Health grant numbers P41EB015909 (SM) and R01NS084957 (SM); grants from Stanley (AS), S-R/RUSK (AS) and NARSAD (AS). Some of the participant recruitment supported by Tanabe Mitsubishi Pharm. Co. Ltd. (AS), and a Wellcome Trust fellowship grant WT087779MA (TWB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:After receiving a complete description of the study, all participants provided written informed consent. The study design was approved by the institutional review boards of all sites: approved by Hammersmith Hospital Research Ethics Committee (IoPPN); approved by Johns Hopkins Medicine Institutional Review Board (JHM IRB) (JHU); approved by Research Ethical Committee of Kanazawa Medical University (KMU); approved by Kyoto University Graduate School and Faculty of Medicine, Ethics Committee (Kyoto); approval by Research Ethics Committee, Osaka University (OSK); approved by Research Ethics Committee of the Faculty of Medicine of the University of Tokyo (Tokyo); and approved by Ethics Committee, University of Toyama (TYM).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be provided upon reasonable request after MTA.